Literature DB >> 21822233

Newsmaker: Lycera.

Ken Garber.   

Abstract

Mesh:

Substances:

Year:  2011        PMID: 21822233     DOI: 10.1038/nbt0811-679

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  1 in total

1.  Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2011-06-07       Impact factor: 54.908

  1 in total
  4 in total

1.  Footrace to clinic heats up for T-cell nuclear receptor inhibitors.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2013-05       Impact factor: 54.908

Review 2.  Targeting IL-17 and TH17 cells in chronic inflammation.

Authors:  Pierre Miossec; Jay K Kolls
Journal:  Nat Rev Drug Discov       Date:  2012-10       Impact factor: 84.694

3.  RORγt-specific transcriptional interactomic inhibition suppresses autoimmunity associated with TH17 cells.

Authors:  Tae-Yoon Park; Sung-Dong Park; Jen-Young Cho; Jae-Seung Moon; Na-Yeon Kim; Kyungsoo Park; Rho Hyun Seong; Sang-Won Lee; Tomohiro Morio; Alfred L M Bothwell; Sang-Kyou Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-19       Impact factor: 11.205

4.  Pien Tze Huang Alleviates Relapsing-Remitting Experimental Autoimmune Encephalomyelitis Mice by Regulating Th1 and Th17 Cells.

Authors:  Xuemei Qiu; Qingqing Guo; Xue Liu; Hui Luo; Danping Fan; Yongqi Deng; Hua Cui; Cheng Lu; Ge Zhang; Xiaojuan He; Aiping Lu
Journal:  Front Pharmacol       Date:  2018-10-31       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.